Long-term use of polyurethane breast prostheses: a 14-year experience.
I have used polyurethane prostheses for the past 14 years, implanting 220 implants into 130 patients who desired breast reconstruction after subcutaneous mastectomy or cancer ablation or simply breast augmentation. I theorize that a polyurethane-covered implant resists contracture, retaining its compressibility because the fibroblasts proliferate into the polyurethane in many different directions. When the fibrils contract, the forces of contracture counterbalance one another, resisting contracture. However, when smooth prostheses are implanted, fibrils are directed in a circular fashion around the implant and naturally contract, leading to firmer breasts. There were 115 prostheses inserted following subcutaneous mastectomy, and 22 percent developed contracted capsules. Seven implants became exposed because of skin necroses; one was removed because of a Staphylococcus infection; and two patients developed a combination of polyurethane and silicone granulomas. These developed only with the earlier implant, where there was shedding of the polyurethane sponge layer and silicone bled from the low-viscosity silicone used in the earlier implants. No granulomas were noted with the currently used Surgitek Replicon implant. Eighty-five breasts were reconstructed after cancer ablation with polyurethane implants, and the contracture rate was 2.3 percent. Other complications were minimal. A smaller group of patients had augmentation mammaplasty, and 20 prostheses were placed in 10 patients. A 15 percent contracture rate was noted in this group. In this study, 82 percent of patients were followed for up to 14 years. Capsular contractures occurred in 30 implants between 1 and 11 years, for an average recurrence at 6.3 years. The overall contracture rate was 13 percent. Other complications were minimal. All implants were placed subcutaneously or subglandularly, and all were drained.
V R
VR
Pennisi
D001940:Breast / Q000601:surgery*; D001941:Breast Diseases / Q000209:etiology; D003286:Contracture / Q000209:etiology / Q000517:prevention & control; D005260:Female; D005347:Fibroblasts / Q000502:physiology; D005500:Follow-Up Studies; D005549:Foreign-Body Reaction / Q000503:physiopathology; D006099:Granuloma / Q000209:etiology; D006801:Humans; D009336:Necrosis / Q000209:etiology; D011140:Polyurethanes; D019736:Prostheses and Implants / Q000009:adverse effects*; D011474:Prosthesis Design; D012867:Skin / Q000473:pathology; D013518:Surgery, Plastic / Q000009:adverse effects*
D011140:Polyurethanes